Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ARS Pharmaceuticals ( (SPRY) ) just unveiled an announcement.
On March 9, 2026, ARS Pharmaceuticals reported fourth-quarter and full-year 2025 results, highlighting $84.3 million in total 2025 revenue, including $72.2 million from U.S. neffy sales in its first full commercial year, alongside a net loss of $171.3 million and a year-end cash position of $245.0 million that management expects will fund operations through anticipated cash-flow break-even. The company detailed rapid U.S. adoption of neffy, expanding payor coverage, an intensified direct-to-consumer push and sales force expansion, as well as key international milestones such as approvals in China and Australia and a positive EMA opinion for EURneffy, underscoring its strategy to build a global, durable anaphylaxis franchise despite ongoing heavy commercial and marketing investments.
The most recent analyst rating on (SPRY) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on ARS Pharmaceuticals stock, see the SPRY Stock Forecast page.
Spark’s Take on SPRY Stock
According to Spark, TipRanks’ AI Analyst, SPRY is a Neutral.
The score is primarily held back by weak financial sustainability—large TTM losses and heavy free-cash-flow burn despite strong revenue growth and margins. Earnings call commentary is supportive due to accelerating Q3 revenue and strategic access initiatives backed by strong liquidity, while technicals are modestly constructive (above key shorter MAs, positive MACD) but not fully recovered versus the 200-day trend. Valuation remains constrained by negative earnings and no dividend support.
To see Spark’s full report on SPRY stock, click here.
More about ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., based in San Diego, is a biopharmaceutical company focused on treatments that protect at-risk patients from allergic reactions that can lead to anaphylaxis. Its lead product is neffy, an epinephrine nasal spray that is the first needle-free epinephrine treatment approved by both the U.S. Food and Drug Administration and the European Commission for Type I allergic reactions, including anaphylaxis.
Average Trading Volume: 1,443,306
Technical Sentiment Signal: Sell
Current Market Cap: $895.6M
See more data about SPRY stock on TipRanks’ Stock Analysis page.